Hib-meningococcal vaccine groups C and Y conjugate - GlaxoSmithKline

Drug Profile

Hib-meningococcal vaccine groups C and Y conjugate - GlaxoSmithKline

Alternative Names: 792014; GSK-792014; Hib-MenCY-TT vaccine - GlaxoSmithKline; HibMenCY-TT; MenHibrix

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections; Meningococcal group C infections; Meningococcal group Y infections

Most Recent Events

  • 31 Mar 2016 GlaxoSmithKline completes a phase III trial for Haemophilus infections and Meningococcal group C & Y infections in USA (NCT01978093)
  • 14 Nov 2013 GlaxoSmithKline plans a phase III trial for Haemophilus infections and Meningococcal group C & Y infections in USA (NCT01978093)
  • 01 Jul 2012 Launched for Haemophilus infections in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top